Could Continuous Glucose Monitoring Become a Tool for Earlier Diabetes Detection?

Today, doctors diagnose diabetes using three main approaches: fasting plasma glucose tests, oral glucose tolerance tests (OGTT), and hemoglobin A1c (HbA1c) measurement. Each provides valuable information, but they all have a limitation—they capture only snapshots or averages of blood sugar over time.

Continuous glucose monitoring devices work differently. Worn on the skin, CGM systems track glucose levels in real time, revealing patterns and fluctuations throughout the day and night. Researchers now suggest that this detailed glucose picture might detect dysglycemia (abnormal blood sugar patterns) earlier than traditional tests can.

Type 1 diabetes progresses through stages. Stage 2 represents a pivotal moment—it's when autoimmune destruction of insulin-producing cells is underway, but symptoms haven't yet appeared. This stage represents what researchers call a 'critical opportunity for intervention before progression to Stage 3 disease.'

If CGM could reliably detect Stage 2 diabetes in people who already have islet autoantibodies (markers of autoimmune activity), it could identify who is most likely to progress to symptomatic disease. This early identification could help people qualify for monitoring, confirmatory testing, or enrollment in prevention trials.

The researchers propose a graduated framework: CGM could start as an adjunctive tool (used alongside existing tests), then mature into an independent diagnostic criterion. However, they emphasize that this progression requires rigorous validation.

The strongest evidence exists for Type 1 diabetes. The researchers also suggest CGM might eventually help diagnose Type 2 diabetes in certain populations, though further work is needed in that area.

Before CGM becomes a standard diagnostic tool, prospective clinical studies must compare CGM-derived metrics directly with OGTT, HbA1c, and other established diagnostic methods. Researchers must develop and validate specific glucose thresholds that predict who will progress to diabetes—and who will benefit from early intervention.

If successful, earlier diabetes detection via CGM could shift the focus from managing disease to preventing it, giving patients and clinicians more time to act before symptoms emerge.

Source: Journal of diabetes science and technology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.